CLSI MIC breakpoints (mg/L) used for S. pneumoniae and H. influenzae isolates
| Antibiotic . | S. pneumoniae . | H. influenzae . | ||||
|---|---|---|---|---|---|---|
| S . | I . | R . | S . | I . | R . | |
| Amoxicillin | ≤2 | 4 | ≥8 | – | – | – |
| Amoxicillin/ clavulanic acida | ≤2 | 4 | ≥8 | ≤4 | – | ≥8 |
| Ampicillin | – | – | – | ≤1 | 2 | ≥4 |
| Penicillin (2.4 g 2 MU × 4–6 IV) | ≤2 | 4 | ≥8 | – | – | – |
| Penicillin (oral) | ≤0.06 | 0.12–1 | ≥2 | – | – | – |
| Cefaclor | ≤1 | 2 | ≥4 | ≤8 | 16 | ≥32 |
| Cefdinir | ≤0.5 | 1 | ≥2 | ≤1 | – | – |
| Cefditoren | – | – | – | – | – | – |
| Cefixime | – | – | – | ≤1 | – | – |
| Cefpodoxime | ≤0.5 | 1 | ≥2 | ≤2 | – | – |
| Ceftriaxone | ≤1 | 2 | ≥4 | ≤2 | – | – |
| Cefuroximeb | ≤1 | 2 | ≥4 | ≤4 | 8 | ≥16 |
| Azithromycin | ≤0.5 | 1 | ≥2 | ≤4 | – | – |
| Clarithromycin | ≤0.25 | 0.5 | ≥1 | ≤8 | 16 | ≥32 |
| Erythromycin | ≤0.25 | 0.5 | ≥1 | – | – | – |
| Levofloxacin | ≤2 | 4 | ≥8 | ≤2 | – | – |
| Moxifloxacin | ≤1 | 2 | ≥4 | ≤1 | – | – |
| Trimethoprim/ sulfamethoxazolec | ≤0.5 | 1–2 | ≥4 | ≤0.5 | 1–2 | ≥4 |
| Antibiotic . | S. pneumoniae . | H. influenzae . | ||||
|---|---|---|---|---|---|---|
| S . | I . | R . | S . | I . | R . | |
| Amoxicillin | ≤2 | 4 | ≥8 | – | – | – |
| Amoxicillin/ clavulanic acida | ≤2 | 4 | ≥8 | ≤4 | – | ≥8 |
| Ampicillin | – | – | – | ≤1 | 2 | ≥4 |
| Penicillin (2.4 g 2 MU × 4–6 IV) | ≤2 | 4 | ≥8 | – | – | – |
| Penicillin (oral) | ≤0.06 | 0.12–1 | ≥2 | – | – | – |
| Cefaclor | ≤1 | 2 | ≥4 | ≤8 | 16 | ≥32 |
| Cefdinir | ≤0.5 | 1 | ≥2 | ≤1 | – | – |
| Cefditoren | – | – | – | – | – | – |
| Cefixime | – | – | – | ≤1 | – | – |
| Cefpodoxime | ≤0.5 | 1 | ≥2 | ≤2 | – | – |
| Ceftriaxone | ≤1 | 2 | ≥4 | ≤2 | – | – |
| Cefuroximeb | ≤1 | 2 | ≥4 | ≤4 | 8 | ≥16 |
| Azithromycin | ≤0.5 | 1 | ≥2 | ≤4 | – | – |
| Clarithromycin | ≤0.25 | 0.5 | ≥1 | ≤8 | 16 | ≥32 |
| Erythromycin | ≤0.25 | 0.5 | ≥1 | – | – | – |
| Levofloxacin | ≤2 | 4 | ≥8 | ≤2 | – | – |
| Moxifloxacin | ≤1 | 2 | ≥4 | ≤1 | – | – |
| Trimethoprim/ sulfamethoxazolec | ≤0.5 | 1–2 | ≥4 | ≤0.5 | 1–2 | ≥4 |
S, susceptible; I, intermediate; R, resistant; –, not applicable.
Amoxicillin/clavulanic acid was tested at a 2:1 amoxicillin to clavulanic acid ratio; breakpoints are expressed as the amoxicillin component.
Breakpoints used are for cefuroxime axetil (oral).
Trimethoprim/sulfamethoxazole was tested at a 1:19 trimethoprim to sulfamethoxazole ratio; breakpoints are expressed as the trimethoprim component.
CLSI MIC breakpoints (mg/L) used for S. pneumoniae and H. influenzae isolates
| Antibiotic . | S. pneumoniae . | H. influenzae . | ||||
|---|---|---|---|---|---|---|
| S . | I . | R . | S . | I . | R . | |
| Amoxicillin | ≤2 | 4 | ≥8 | – | – | – |
| Amoxicillin/ clavulanic acida | ≤2 | 4 | ≥8 | ≤4 | – | ≥8 |
| Ampicillin | – | – | – | ≤1 | 2 | ≥4 |
| Penicillin (2.4 g 2 MU × 4–6 IV) | ≤2 | 4 | ≥8 | – | – | – |
| Penicillin (oral) | ≤0.06 | 0.12–1 | ≥2 | – | – | – |
| Cefaclor | ≤1 | 2 | ≥4 | ≤8 | 16 | ≥32 |
| Cefdinir | ≤0.5 | 1 | ≥2 | ≤1 | – | – |
| Cefditoren | – | – | – | – | – | – |
| Cefixime | – | – | – | ≤1 | – | – |
| Cefpodoxime | ≤0.5 | 1 | ≥2 | ≤2 | – | – |
| Ceftriaxone | ≤1 | 2 | ≥4 | ≤2 | – | – |
| Cefuroximeb | ≤1 | 2 | ≥4 | ≤4 | 8 | ≥16 |
| Azithromycin | ≤0.5 | 1 | ≥2 | ≤4 | – | – |
| Clarithromycin | ≤0.25 | 0.5 | ≥1 | ≤8 | 16 | ≥32 |
| Erythromycin | ≤0.25 | 0.5 | ≥1 | – | – | – |
| Levofloxacin | ≤2 | 4 | ≥8 | ≤2 | – | – |
| Moxifloxacin | ≤1 | 2 | ≥4 | ≤1 | – | – |
| Trimethoprim/ sulfamethoxazolec | ≤0.5 | 1–2 | ≥4 | ≤0.5 | 1–2 | ≥4 |
| Antibiotic . | S. pneumoniae . | H. influenzae . | ||||
|---|---|---|---|---|---|---|
| S . | I . | R . | S . | I . | R . | |
| Amoxicillin | ≤2 | 4 | ≥8 | – | – | – |
| Amoxicillin/ clavulanic acida | ≤2 | 4 | ≥8 | ≤4 | – | ≥8 |
| Ampicillin | – | – | – | ≤1 | 2 | ≥4 |
| Penicillin (2.4 g 2 MU × 4–6 IV) | ≤2 | 4 | ≥8 | – | – | – |
| Penicillin (oral) | ≤0.06 | 0.12–1 | ≥2 | – | – | – |
| Cefaclor | ≤1 | 2 | ≥4 | ≤8 | 16 | ≥32 |
| Cefdinir | ≤0.5 | 1 | ≥2 | ≤1 | – | – |
| Cefditoren | – | – | – | – | – | – |
| Cefixime | – | – | – | ≤1 | – | – |
| Cefpodoxime | ≤0.5 | 1 | ≥2 | ≤2 | – | – |
| Ceftriaxone | ≤1 | 2 | ≥4 | ≤2 | – | – |
| Cefuroximeb | ≤1 | 2 | ≥4 | ≤4 | 8 | ≥16 |
| Azithromycin | ≤0.5 | 1 | ≥2 | ≤4 | – | – |
| Clarithromycin | ≤0.25 | 0.5 | ≥1 | ≤8 | 16 | ≥32 |
| Erythromycin | ≤0.25 | 0.5 | ≥1 | – | – | – |
| Levofloxacin | ≤2 | 4 | ≥8 | ≤2 | – | – |
| Moxifloxacin | ≤1 | 2 | ≥4 | ≤1 | – | – |
| Trimethoprim/ sulfamethoxazolec | ≤0.5 | 1–2 | ≥4 | ≤0.5 | 1–2 | ≥4 |
S, susceptible; I, intermediate; R, resistant; –, not applicable.
Amoxicillin/clavulanic acid was tested at a 2:1 amoxicillin to clavulanic acid ratio; breakpoints are expressed as the amoxicillin component.
Breakpoints used are for cefuroxime axetil (oral).
Trimethoprim/sulfamethoxazole was tested at a 1:19 trimethoprim to sulfamethoxazole ratio; breakpoints are expressed as the trimethoprim component.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
